MCID: ERY017
MIFTS: 49

Erythema Elevatum Diutinum

Categories: Rare diseases, Skin diseases, Cardiovascular diseases, Bone diseases

Aliases & Classifications for Erythema Elevatum Diutinum

MalaCards integrated aliases for Erythema Elevatum Diutinum:

Name: Erythema Elevatum Diutinum 12 50 56 42 14 69

Characteristics:

Orphanet epidemiological data:

56
erythema elevatum diutinum
Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060567
ICD10 33 L95.1
MeSH 42 C535509
Orphanet 56 ORPHA90000
MESH via Orphanet 43 C535509
UMLS via Orphanet 70 C0263398
ICD10 via Orphanet 34 L95.1
UMLS 69 C0263398

Summaries for Erythema Elevatum Diutinum

NIH Rare Diseases : 50 erythema elevatum diutinum is a rare type of chronic cutaneous vasculitis characterized by red, purple, brown or yellow papules, plaques (thick, red patches of skin), or nodules.these lesions are located mainly on the knees, elbows, hands, feet, face, genitals and buttocks. although it is a chronic condition, most cases respond well to treatment with dapsone. the cause of this condition remains unknown.  last updated: 4/13/2010

MalaCards based summary : Erythema Elevatum Diutinum is related to fallopian tube carcinoma and plantar wart, and has symptoms including myalgia, skin rash and arthralgia. An important gene associated with Erythema Elevatum Diutinum is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and Cell adhesion molecules (CAMs). The drugs Heparin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and bone, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A vasculitis characterised by red, purple, brown or yellow papules (raised spot), plaques, or nodules, found on the backs of the hands, other extensor surfaces overlying joints, and on the buttocks.

Wikipedia : 72 Erythema elevatum diutinum is a form of... more...

Related Diseases for Erythema Elevatum Diutinum

Diseases related to Erythema Elevatum Diutinum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
id Related Disease Score Top Affiliating Genes
1 fallopian tube carcinoma 10.7 CD79A CXCL8
2 plantar wart 10.6 CD79A CXCL8
3 bullous retinoschisis 10.6 CD79A CXCL8
4 alcoholic neuropathy 10.6 CD40LG CD79A
5 calloso-genital dysplasia 10.6 CD40LG CD79A
6 variola major 10.6 CD40LG CD79A
7 mu chain disease 10.6 CD40LG CD79A
8 rabies 10.6 CD40LG CD79A
9 familial retinoblastoma 10.6 CD40LG CD79A
10 microinvasive cervical squamous cell carcinoma 10.5 CD40LG CD79A
11 fetal erythroblastosis 10.5 CD40LG CD79A
12 spinal canal and spinal cord meningioma 10.5 CD40LG CD79A
13 trichostrongyloidiasis 10.5 CD40LG CD79A
14 leukodystrophy 10.5 CD40LG CD79A
15 retinal microaneurysm 10.5 CD40LG CD79A
16 heart septal defect 10.5 CD40LG CD79A
17 cryptorchidism arachnodactyly mental retardation 10.5 CD40LG CD79A
18 acute kidney tubular necrosis 10.5 CD40LG CD79A
19 secretory meningioma 10.5 CD40LG CD79A
20 hodgkin's lymphoma, nodular sclerosis 10.5 CD40LG CD79A
21 imperforate oropharynx-costo vetebral anomalies 10.5 CD40LG CD79A
22 transient hypogammaglobulinemia 10.5 CD40LG CD79A
23 benign epilepsy with centrotemporal spikes 10.5 CD40LG CD79A
24 tongue cancer 10.5 CD40LG CD79A
25 hydrops of gallbladder 10.5 CD40LG CD79A
26 gamma heavy chain disease 10.5 CD40LG CD79A
27 diabetic angiopathy 10.5 CD40LG CD79A
28 rosacea conjunctivitis 10.5 CD40LG CD79A
29 viral meningitis 10.5 CD40LG CD79A
30 heart fibrosarcoma 10.5 CD40LG CD79A
31 alopecia areata 10.5 CD40LG CD79A
32 kidney carcinoma in situ 10.5 CD40LG CD79A
33 dumping syndrome 10.5 CD40LG CD79A
34 leiomyosarcoma 10.5 CD40LG CD79A
35 periarthritis 10.5 CD40LG CD79A
36 generalized atherosclerosis 10.5 CD40LG CD79A
37 colonic benign neoplasm 10.5 CD40LG CD79A
38 cerebral neuroblastoma 10.5 CD40LG CD79A
39 pancreatic vasoactive intestinal peptide producing tumor 10.5 CD40LG CD79A
40 oculo-cerebral dysplasia 10.5 CD40LG CD79A
41 aniseikonia 10.5 CD40LG CD79A
42 gestational diabetes 10.5 CD40LG CD79A
43 polyneuropathy due to drug 10.5 CD40LG CD79A
44 chronic mucocutaneous candidiasis 10.5 CD40LG CD79A
45 cutaneous ganglioneuroma 10.5 CD40LG CD79A
46 acute hemorrhagic encephalitis 10.5 CD40LG CD79A
47 mental retardation, autosomal dominant 19 10.5 CD40LG CD79A
48 adie pupil 10.5 CD40LG CD79A
49 immunoglobulin alpha deficiency 10.5 CD40LG CD79A
50 mitochondrial encephalomyopathy 10.5 CD40LG CD79A

Graphical network of the top 20 diseases related to Erythema Elevatum Diutinum:



Diseases related to Erythema Elevatum Diutinum

Symptoms & Phenotypes for Erythema Elevatum Diutinum

Human phenotypes related to Erythema Elevatum Diutinum:

56 32 (show all 8)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myalgia 56 32 occasional (7.5%) Occasional (29-5%) HP:0003326
2 skin rash 56 32 hallmark (90%) Very frequent (99-80%) HP:0000988
3 arthralgia 56 32 hallmark (90%) Very frequent (99-80%) HP:0002829
4 abnormal blistering of the skin 56 32 frequent (33%) Frequent (79-30%) HP:0008066
5 skin vesicle 56 32 frequent (33%) Frequent (79-30%) HP:0200037
6 increased antibody level in blood 56 32 frequent (33%) Frequent (79-30%) HP:0010702
7 skin nodule 56 32 occasional (7.5%) Occasional (29-5%) HP:0200036
8 vasculitis in the skin 56 32 hallmark (90%) Very frequent (99-80%) HP:0200029

MGI Mouse Phenotypes related to Erythema Elevatum Diutinum:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.8 CD34 CD40LG CD79A GATA3 PECAM1 S100A9
2 hematopoietic system MP:0005397 9.76 CD34 CD40LG CD79A F13A1 GATA3 PECAM1
3 homeostasis/metabolism MP:0005376 9.56 TBX21 CD34 CD40LG CD79A F13A1 GATA3
4 immune system MP:0005387 9.17 CD34 CD40LG CD79A GATA3 PECAM1 S100A9

Drugs & Therapeutics for Erythema Elevatum Diutinum

Drugs for Erythema Elevatum Diutinum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
2
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
3
Budesonide Approved Phase 4 51333-22-3 63006 5281004
4
Canagliflozin Approved Phase 4 842133-18-0
5
Insulin Aspart Approved Phase 4,Phase 3 116094-23-6 16132418
6
Insulin Glargine Approved Phase 4 160337-95-1
7
Insulin-glulisine Approved Phase 4 207748-29-6
8
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
9
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
10
Goserelin Approved Phase 4 65807-02-5 47725 5311128
11
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
13
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
14 Hormone Antagonists Phase 4,Phase 3,Phase 2
15 Hormones Phase 4,Phase 3,Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
17 calcium heparin Phase 4,Phase 3
18 Antimetabolites Phase 4,Phase 3,Phase 2
19 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2
21 Dermatologic Agents Phase 4,Phase 3,Phase 2
22 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
24 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
25 Vitamin B Complex Phase 4,Phase 3,Phase 2
26 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
27 Contraceptive Agents Phase 4,Phase 3,Phase 2
28 Adrenergic Agents Phase 4,Phase 3
29 Adrenergic Agonists Phase 4,Phase 3
30 Adrenergic beta-2 Receptor Agonists Phase 4
31 Adrenergic beta-Agonists Phase 4
32 Anti-Asthmatic Agents Phase 4,Phase 3
33 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
34 Autonomic Agents Phase 4,Phase 3,Phase 2
35 Bronchodilator Agents Phase 4,Phase 3
36 Budesonide, Formoterol Fumarate Drug Combination Phase 4
37 Formoterol Fumarate Phase 4
38 glucocorticoids Phase 4,Phase 3,Phase 2
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
41 Respiratory System Agents Phase 4,Phase 3
42 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
43 Biphasic Insulins Phase 4,Phase 3
44 Coagulants Phase 4
45 insulin Phase 4,Phase 3
46 Insulin aspart, insulin aspart protamine drug combination 30:70 Phase 4,Phase 3
47 Insulin degludec, insulin aspart drug combination Phase 4,Phase 3
48 Insulin, Globin Zinc Phase 4,Phase 3
49 Insulin, Long-Acting Phase 4,Phase 3
50 Pharmaceutical Solutions Phase 4

Interventional clinical trials:

(show top 50) (show all 87)

id Name Status NCT ID Phase Drugs
1 Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma Completed NCT02062463 Phase 4 Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX;SYMBICORT TURBOHALER budesonide and formoterol fumarate
2 A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus Completed NCT01989754 Phase 4 Placebo;Canagliflozin, 100 mg;Canagliflozin, 300 mg
3 Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients Completed NCT00965549 Phase 4 INSULIN GLARGINE (HOE901);Insulin aspart;Insulin Glulisine
4 Local Phase 4 Pan-European SMART Study Completed NCT00463866 Phase 4 Budesonide/formoterol
5 AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers Completed NCT01084577 Phase 4
6 A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. Active, not recruiting NCT02752776 Phase 4 Secukinumab
7 A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage Terminated NCT01661140 Phase 4 Methotrexate (stable dose);Tocilizumab;Methotrexate (tapering dose)
8 GP Extended Action Triptorelin Terminated NCT01673984 Phase 4 Decapeptyl® SR 22.5mg;Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
9 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Unknown status NCT00559858 Phase 3
10 Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer Unknown status NCT00392535 Phase 3 cyproterone acetate;releasing hormone agonist therapy
11 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
12 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
13 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed NCT00412984 Phase 3 warfarin;apixaban
14 A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease Completed NCT00501059 Phase 3 Aspirin (Acetylsalicylic acid, BAYE4465);Placebo
15 A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer Completed NCT01262651 Phase 3 Sativex®;Placebo (GA-0034)
16 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
17 A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea Completed NCT00196794 Phase 3 Tolevamer potassium-sodium (GT267-004)
18 A Study of RoActemra/Actemra (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Completed NCT02046603 Phase 3 DMARDs;corticosteroids;tocilizumab [RoActemra/Actemra]
19 Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension Completed NCT01788358 Phase 3 Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
20 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed NCT01764633 Phase 3 Effective statin therapy
21 A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer Completed NCT01424566 Phase 3 Sativex®;Placebo (product code GA0034)
22 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed NCT01336023 Phase 3 insulin degludec/liraglutide;insulin degludec;liraglutide
23 Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease Completed NCT01313676 Phase 3 fluticasone furoate/vilanterol;fluticasone furoate;vilanterol
24 An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy Completed NCT00883753 Phase 3 tocilizumab [RoActemra/Actemra]
25 An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. Completed NCT00750880 Phase 3 tocilizumab [RoActemra/Actemra]
26 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM Completed NCT00736099 Phase 3 linagliptine 5 mg;linagliptine 5 mg and pioglitazone 30 mg
27 Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients Completed NCT00660907 Phase 3 dapagliflozin;glipizide;metformin hydrochloride
28 BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes Completed NCT00602472 Phase 3 linagliptin;placebo
29 Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00400153 Phase 3 Atrovent Respimat (20 mcg);COMBIVENT MDI (36/206 mcg);Combivent Respimat (20 mcg/100 mcg);Placebo via corresponding inhaler for blinding purposes
30 Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes Completed NCT00184600 Phase 3 biphasic insulin aspart;insulin detemir;insulin aspart
31 A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer Completed NCT00069121 Phase 3 capecitabine [Xeloda];Oxaliplatin;Oxaliplatin;Leucovorin;5 FU
32 Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU) Completed NCT00479661 Phase 3 Dexmedetomidine;Propofol
33 A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain Completed NCT01439100 Phase 3 Oxycodone/Naloxone Prolonged Release tablets;Placebo
34 Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain Completed NCT01337089 Phase 3 Sativex®
35 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
36 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed NCT00633893 Phase 3 Apixaban;Placebo
37 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
38 Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours Recruiting NCT02804815 Phase 3 Aspirin 100mg;Aspirin 300mg;Placebo 100mg;Placebo 300mg
39 Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab Recruiting NCT03107793 Phase 3 Ustekinumab
40 Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease Recruiting NCT02914600 Phase 3 Filgotinib;Placebo
41 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease Recruiting NCT02914561 Phase 3 Filgotinib;Placebo to match filgotinib
42 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Recruiting NCT02914535 Phase 3 Filgotinib;Placebo
43 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis Recruiting NCT02914522 Phase 3 Filgotinib;Placebo to match filgotinib
44 A Study to Assess the Efficacy and Safety of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients Recruiting NCT02605434 Phase 3 Accordion Pill™ Carbidopa/Levodopa;Sinemet®;Placebo -AP-CD/LD;Placebo- Sinemet
45 An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease Recruiting NCT02542696 Phase 3 APL-130277
46 Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Recruiting NCT02540954 Phase 3 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
47 Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Recruiting NCT02403323 Phase 3 etrolizumab
48 A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease Recruiting NCT02394028 Phase 3 Etrolizumab 210 mg;Etrolizumab 105 mg;Placebo
49 A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02136069 Phase 3 etrolizumab;infliximab
50 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3 Etrolizumab

Search NIH Clinical Center for Erythema Elevatum Diutinum

Cochrane evidence based reviews: erythema elevatum diutinum

Genetic Tests for Erythema Elevatum Diutinum

Anatomical Context for Erythema Elevatum Diutinum

MalaCards organs/tissues related to Erythema Elevatum Diutinum:

39
Skin, Breast, Bone, B Cells, Neutrophil, Prostate, Liver

Publications for Erythema Elevatum Diutinum

Articles related to Erythema Elevatum Diutinum:

(show top 50) (show all 190)
id Title Authors Year
1
Erythema elevatum diutinum presenting with palmoplantar keratoderma. ( 28512994 )
2017
2
Erythema elevatum diutinum in a healthy child. ( 28397292 )
2017
3
Erythema elevatum diutinum in Crohn's disease-associated Spondyloarthritis - a rare vasculitis, an unusual association. ( 28917218 )
2017
4
Erythema elevatum diutinum involving palms and soles: a case report and literature review. ( 28469800 )
2017
5
Erythema Elevatum Diutinum. ( 28183422 )
2017
6
Erythema elevatum diutinum-associated with loss of the uvula. ( 28443312 )
2017
7
Vesiculobullous variant of erythema elevatum diutinum. ( 28639709 )
2017
8
A rare case of erythema elevatum diutinum presenting as diffuse neuropathy. ( 28050587 )
2017
9
Erythema, Elevatum Diutinum ( 28846276 )
2017
10
Chronic Localized Fibrosing Leukocytoclastic Vasculitis Associated With Lymphedema, Intralymphatic and Intravascular Lymphocytosis, and Chronic Myelogenous Leukemia: A Case Report of Unilateral Erythema Elevatum Diutinum. ( 27930381 )
2016
11
Erythema elevatum diutinum in acquired immune deficiency syndrome: Can it be an immune reconstitution inflammatory syndrome? ( 27190420 )
2016
12
Erythema elevatum diutinum in association with IgA monoclonal gammopathy: A rare case report. ( 27559509 )
2016
13
Granuloma Faciale and Erythema Elevatum Diutinum in Relation to Immunoglobulin G4-Related Disease: An Appraisal of 32 Cases. ( 27124923 )
2016
14
Pediatric case of microscopic polyangiitis with skin manifestations resembling vesiculobullous type erythema elevatum diutinum with immunoglobulin A antineutrophil cytoplasmic antibody. ( 27097593 )
2016
15
A Case of Erythema Elevatum Diutinum With Pancytopenia: Focus on Dapsone-Induced Hematologic Side Effects and Colchicine as a Safe Treatment Option. ( 26461818 )
2015
16
Erythema elevatum diutinum and hypothyroidism: coincidence or causal relationship? ( 26375227 )
2015
17
Erythema elevatum diutinum: an atypical presentation. ( 25521326 )
2015
18
A case of mistaken identity: unilateral erythema elevatum diutinum associated with IgA paraproteinaemia. ( 25754401 )
2015
19
Erythema elevatum diutinum coexisting with ankylosing spondylitis. ( 27708930 )
2015
20
An atypical distribution of erythema elevatum diutinum. ( 24479627 )
2014
21
Erythema elevatum diutinum: a review of presentation and treatment. ( 25288365 )
2014
22
An unusual case of Sweet syndrome in a child: overlapping presentation with erythema elevatum diutinum. ( 24521734 )
2014
23
Case of Erythema Elevatum Diutinum Associated With IgA Paraproteinemia Successfully Controlled With Thalidomide and Plasma Exchange. ( 25257541 )
2014
24
Nodular Erythema Elevatum Diutinum Mimicking Kaposi's Sarcoma in a Human Immunodeficiency Virus Infected Patient. ( 25484391 )
2014
25
Erythema Elevatum Diutinum (EED): A Distinctive Vasculitis with Acute-on-Chronic Features. ( 24652434 )
2014
26
An unusual case of erythema elevatum diutinum with penile and laryngeal manifestations. ( 24413401 )
2014
27
Erythema elevatum diutinum in association with dermatitis herpetiformis. ( 24616856 )
2014
28
Erythema elevatum diutinum: a new vesiculobullous case. ( 24001509 )
2013
29
Novel use of topical dapsone 5% gel for erythema elevatum diutinum: safer and effective. ( 23652900 )
2013
30
Atypical erythema elevatum diutinum or extrafacial granuloma faciale? ( 23253514 )
2013
31
Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet's syndrome: the concept of neutrophilic disease. ( 24073904 )
2013
32
Erythema elevatum diutinum. ( 23487831 )
2013
33
Erythema elevatum diutinum. ( 23442466 )
2013
34
Successful combination therapy with dapsone and cyclosporine for erythema elevatum diutinum with unusual appearance. ( 22132683 )
2012
35
A case of erythema elevatum diutinum associated with peripheral ulcerative keratitis. ( 22309340 )
2012
36
Alternative procedure to allow continuation of dapsone therapy despite serious adverse reaction in a case of dapsone-sensitive erythema elevatum diutinum. ( 22508198 )
2012
37
Erythema elevatum diutinum with oral ulceration. ( 22284024 )
2012
38
Acceleration of pulmonary interstitial fibrosis in a patient with myeloperoxidase-antineutrophil cytoplasmic antibody-positive erythema elevatum diutinum. ( 21839335 )
2011
39
Erythema elevatum diutinum - a chronic leukocytoclastic vasculitis microscopically indistinguishable from granuloma faciale? ( 21883365 )
2011
40
Progressive keratolysis with pseudopterygium associated with erythema elevatum diutinum. ( 21211842 )
2011
41
A case of extensive erosive and bullous erythema elevatum diutinum in a patient diagnosed with human immunodeficiency virus (HIV). ( 21781074 )
2011
42
Erythema elevatum diutinum associated with dermatomyositis. ( 21496713 )
2011
43
Erythema elevatum diutinum associated with peripheral ulcerative keratitis. ( 20569285 )
2011
44
Erythema elevatum diutinum: an "idiopathic" case. ( 21810392 )
2011
45
Dapsone Hypersensitivity Syndrome That Occurred during Treatment of Pediatric Patient with Erythema Elevatum Diutinum. ( 22346260 )
2011
46
Is IgA antineutrophil cytoplasmic antibody a marker for patients with erythema elevatum diutinum? A further three cases demonstrating this association. ( 21143463 )
2011
47
Erythema elevatum diutinum in systemic lupus erythematosus. ( 20652813 )
2011
48
Erythema elevatum diutinum associated with scleritis. ( 23130212 )
2011
49
Erythema elevatum diutinum mimicking a vesiculobullous disease. ( 22126877 )
2011
50
Erythema elevatum diutinum with verrucous carcinoma: a rare association. ( 20657132 )
2010

Variations for Erythema Elevatum Diutinum

Expression for Erythema Elevatum Diutinum

Search GEO for disease gene expression data for Erythema Elevatum Diutinum.

Pathways for Erythema Elevatum Diutinum

GO Terms for Erythema Elevatum Diutinum

Cellular components related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD34 CD40LG CD79A PECAM1

Biological processes related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.5 CD34 CD40LG TBX21
2 T cell differentiation GO:0030217 9.4 GATA3 TBX21
3 B cell proliferation GO:0042100 9.37 CD40LG CD79A
4 positive regulation of interleukin-10 production GO:0032733 9.26 CD34 CD40LG
5 positive regulation of interleukin-4 production GO:0032753 9.16 CD40LG GATA3
6 lymphocyte migration GO:0072676 8.96 GATA3 TBX21
7 glomerular endothelium development GO:0072011 8.62 CD34 PECAM1

Sources for Erythema Elevatum Diutinum

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....